DexCom (DexCom) Risk Assessment

View and export this data going back to 2005. Start your Free Trial

What is DexCom Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of DexCom is: Moderate Risk: Sensitive, better choose undervalued stock.

Competitive Comparison of DexCom's Risk Assessment

For the Medical Devices subindustry, DexCom's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DexCom's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Risk Assessment distribution charts can be found below:

* The bar in red indicates where DexCom's Risk Assessment falls into.

DexCom (NAS:DXCM) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

DexCom Risk Assessment Related Terms

Thank you for viewing the detailed overview of DexCom's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

DexCom (DexCom) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » DexCom Inc (NAS:DXCM) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

DXCM:Mexico DC4:Germany DC4:Germany DC4:Germany DC4:Germany D1EX34:Brazil DXCM:Austria

Address

6340 Sequence Drive, San Diego, CA, USA, 92121

Website

https://www.dexcom.com

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Executives

Sadie Stern	officer: Chief Human Resources Officer	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Steven R Altman	director
Kevin R Sayer	director
Jereme M Sylvain	officer: SVP, Finance & CAO	6340 SEQUENCE DRIVE, SAN DIEGO X1 92121
Jacob Steven Leach	officer: SVP, Research & Development	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Nicholas Augustinos	director	754 GRAND VIEW AVENUE, SAN FRANCISCO CA 94114
Micheal Jon Brown	officer: EVP, Chief Legal Officer	6340 SEQUENCE DR, SAN DIEGO CA 92121
Steven Robert Pacelli	officer: Vice President Legal Affairs	5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Girish Naganathan	officer: EVP Chief Technology Officer	C/O DEXCOM, INC., 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Barry J. Regan	officer: EVP Operations	1023 CHERRY ROAD, MEMPHIS TN 38117
Bridgette P Heller	director	TECH DATA CORPORATION, 5350 TECH DATA DRIVE, CLEARWATER FL 33760
Matthew Vincent Dolan	officer: *	6340 SEQUENCE DR, SAN DIEGO CA 92121
Rimma Driscoll	director	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Shelly Ramasamy Selvaraj	officer: SVP Information Technology	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Paul R Flynn	officer: EVP, Global Revenue	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121